CRISPR & Gene Editing
The revolutionary gene-editing technology that allows precise modification of DNA, raising profound ethical questions about designer babies, eugenics, and human enhancement.
OVERVIEW
CRISPR-Cas9 is a gene-editing technology developed by Jennifer Doudna and Emmanuelle Charpentier (who won the 2020 Nobel Prize in Chemistry). It allows scientists to edit DNA sequences with unprecedented precision and efficiency. The technology has been used in clinical trials to treat sickle cell disease, cancer, and inherited blindness. However, it also raises profound ethical concerns. In 2018, Chinese scientist He Jiankui announced the birth of the first CRISPR-edited babies, altering the CCR5 gene to confer HIV resistance — a move widely condemned as unethical and illegal. The technology also enables potential for non-therapeutic human enhancement, genetic inequality, and environmental modification.
KNOWN FACTS
CRISPR clinical trials for sickle cell disease have shown promising results
He Jiankui's experiment created the first heritable gene-edited humans
Multiple countries have banned heritable genome editing
Gene drive technology has been tested in mosquitoes for malaria control
Patents for CRISPR applications are held by competing research groups and corporations
CLAIMS
CRISPR can cure genetic diseases including sickle cell, beta-thalassemia, and some cancers
Heritable human gene editing could create permanent changes to the human gene pool
The technology could be used for genetic enhancement beyond therapeutic applications
Germline editing could lead to a new eugenics movement
Gene drives could deliberately alter or eliminate entire species
EVIDENCE FOR
CRISPR clinical trials for sickle cell disease have shown promising results
He Jiankui's experiment created the first heritable gene-edited humans
Multiple countries have banned heritable genome editing
Gene drive technology has been tested in mosquitoes for malaria control
Patents for CRISPR applications are held by competing research groups and corporations
EVIDENCE AGAINST
Gene editing for therapy is ethically distinct from editing for enhancement
International agreements and national regulations constrain unethical applications
CRISPR off-target effects make germline editing medically risky at current precision
Therapeutic applications could prevent immense suffering from genetic diseases
Public discourse and democratic oversight can guide ethical development
OPEN QUESTIONS
No open questions recorded.
SOURCES
TIMELINE
Doudna and Charpentier publish CRISPR-Cas9 method
First CRISPR clinical trial approved in China
He Jiankui announces CRISPR-edited babies Lulu and Nana
Nobel Prize awarded to Doudna and Charpentier
First CRISPR therapy (Casgevy) approved by UK and US regulators